Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

12.59 +0.99 (+8.53%)

Streaming Delayed Price Updated: 3:59 PM EST, Jan 22, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,223,353
Open	11.76
Bid (Size)	12.58 (800)
Ask (Size)	12.60 (2,200)
Prev. Close	11.60
Today's Range	11.75 - 12.99
52wk Range	5.680 - 13.33
Shares Outstanding	42,734,644
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

January 08, 2026

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+24.4%	+24.4%
1 Month	+21.8%	+21.8%
3 Month	+55.0%	+55.0%
6 Month	+51.1%	+51.1%
1 Year	+20.8%	+20.8%

More News

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

December 08, 2025

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

Via The Motley Fool

Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

December 01, 2025

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

Via The Motley Fool

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

Via The Motley Fool

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

Via The Motley Fool

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Via The Motley Fool

Which stocks are experiencing notable movement on Monday? ↗

November 24, 2025

Via Chartmill

Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

November 10, 2025

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Q3 2025 Earnings Beat Estimates and Announces Strategic Pipeline Refocus ↗

November 06, 2025

Via Chartmill

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 06, 2025

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

November 03, 2025

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

October 25, 2025

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations ↗

October 13, 2025

Via Benzinga

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

September 12, 2025

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

August 21, 2025

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Cullinan (CGEM) Q2 R&D Jumps 68% ↗

August 07, 2025

Via The Motley Fool

CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Reports Wider Q2 2025 Loss, Misses EPS Estimates Amid Rising R&D Costs ↗

August 07, 2025

Via Chartmill

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 07, 2025

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix ↗

June 05, 2025

Via Stocktwits

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases

June 04, 2025

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

May 29, 2025

From Cullinan Therapeutics, Inc.

Via GlobeNewswire

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

May 22, 2025

From Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Cullinan Therapeutics, Inc. - Common Stock publicly traded?

Yes, Cullinan Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Cullinan Therapeutics, Inc. - Common Stock trade on?

Cullinan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cullinan Therapeutics, Inc. - Common Stock?

The ticker symbol for Cullinan Therapeutics, Inc. - Common Stock is CGEM on the Nasdaq Stock Market

What is the current price of Cullinan Therapeutics, Inc. - Common Stock?

The current price of Cullinan Therapeutics, Inc. - Common Stock is 12.59

When was Cullinan Therapeutics, Inc. - Common Stock last traded?

The last trade of Cullinan Therapeutics, Inc. - Common Stock was at 01/22/26 03:59 PM ET

What is the market capitalization of Cullinan Therapeutics, Inc. - Common Stock?

The market capitalization of Cullinan Therapeutics, Inc. - Common Stock is 538.03M

How many shares of Cullinan Therapeutics, Inc. - Common Stock are outstanding?

Cullinan Therapeutics, Inc. - Common Stock has 538M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.